Logo Image
News|Podcasts|September 6, 2024

Beyond the Birthrate: The Societal Costs of Maternal Mortality

Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.

Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon discusses:

  • The broader societal implications of these maternal health issues highlighted in The Commonwealth Fund study
  • The most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make
  • Specific efforts Organon is undertaking to invest in research, education, and its pipeline to focus on critical areas of need in maternal health
  • How her in-practice experience as an OB-GYN are informing Organon's strategic approach to addressing maternal health challenges
  • and more!

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.
Read more
Pharmaceutical Executive daily
Pharmaceutical Executive Daily: FDA Approves Voceryq
FDA grants accelerated approval to INOVIO’s Voceryq to reduce surgical burden in recurrent respiratory papillomatosis, Brox.AI’s Hamish Brocklebank on the three levels of digital clone use cases in pharma, and CytoDyn’s Dr. Jay Lalezari on his path from HIV clinician to CEO.
Read more